JP2023533472A - 肺非結核性真菌感染症を治療するための三重抗生物質固定用量コンビネーション製品、投与レジメン、方法及びキット - Google Patents

肺非結核性真菌感染症を治療するための三重抗生物質固定用量コンビネーション製品、投与レジメン、方法及びキット Download PDF

Info

Publication number
JP2023533472A
JP2023533472A JP2022580214A JP2022580214A JP2023533472A JP 2023533472 A JP2023533472 A JP 2023533472A JP 2022580214 A JP2022580214 A JP 2022580214A JP 2022580214 A JP2022580214 A JP 2022580214A JP 2023533472 A JP2023533472 A JP 2023533472A
Authority
JP
Japan
Prior art keywords
milligrams
fixed dose
clarithromycin
clofazimine
rifabutin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533472A5 (https=
JPWO2022003421A5 (https=
Inventor
ファシ，レザ
ラダイ，ギリアド
アンダーソン，パトリシア
ホフマン，エリオット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of JP2023533472A publication Critical patent/JP2023533472A/ja
Publication of JP2023533472A5 publication Critical patent/JP2023533472A5/ja
Publication of JPWO2022003421A5 publication Critical patent/JPWO2022003421A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022580214A 2020-06-30 2021-06-30 肺非結核性真菌感染症を治療するための三重抗生物質固定用量コンビネーション製品、投与レジメン、方法及びキット Pending JP2023533472A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046335P 2020-06-30 2020-06-30
US202063046322P 2020-06-30 2020-06-30
US63/046,335 2020-06-30
US63/046,322 2020-06-30
PCT/IB2021/000451 WO2022003421A2 (en) 2020-06-30 2021-06-30 Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

Publications (3)

Publication Number Publication Date
JP2023533472A true JP2023533472A (ja) 2023-08-03
JP2023533472A5 JP2023533472A5 (https=) 2024-07-09
JPWO2022003421A5 JPWO2022003421A5 (https=) 2024-07-09

Family

ID=79032054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580214A Pending JP2023533472A (ja) 2020-06-30 2021-06-30 肺非結核性真菌感染症を治療するための三重抗生物質固定用量コンビネーション製品、投与レジメン、方法及びキット

Country Status (11)

Country Link
US (1) US11590154B2 (https=)
EP (1) EP4171546A4 (https=)
JP (1) JP2023533472A (https=)
KR (1) KR20230028502A (https=)
CN (1) CN115768420A (https=)
AU (1) AU2021298936A1 (https=)
BR (1) BR112022026615A2 (https=)
CA (1) CA3187031A1 (https=)
IL (1) IL299287A (https=)
MX (1) MX2023000165A (https=)
WO (1) WO2022003421A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511012A (ja) * 2008-02-08 2011-04-07 レッド ヒル バイオファーマ リミテッド 炎症性腸疾患を治療するための方法および組成物
JP2014526548A (ja) * 2011-09-20 2014-10-06 レッド ヒル バイオファーマ リミテッド 自己免疫疾患を処置するための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR012304A1 (es) 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
US20180273573A1 (en) 2015-10-01 2018-09-27 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
WO2017194734A1 (en) 2016-05-13 2017-11-16 Technische Universität München Means and methods for treating mycobacterial diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511012A (ja) * 2008-02-08 2011-04-07 レッド ヒル バイオファーマ リミテッド 炎症性腸疾患を治療するための方法および組成物
JP2014526548A (ja) * 2011-09-20 2014-10-06 レッド ヒル バイオファーマ リミテッド 自己免疫疾患を処置するための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIN DRUG INVEST, vol. 17, no. 3, JPN6025032437, 1999, pages 171 - 178, ISSN: 0005792950 *
GUT PATHOGENS, vol. Vol.8:32, JPN6025032438, 2016, pages 1 - 8, ISSN: 0005792951 *

Also Published As

Publication number Publication date
US11590154B2 (en) 2023-02-28
US20210401865A1 (en) 2021-12-30
EP4171546A4 (en) 2024-03-13
CA3187031A1 (en) 2022-01-06
IL299287A (en) 2023-02-01
EP4171546A2 (en) 2023-05-03
BR112022026615A2 (pt) 2023-01-24
CN115768420A (zh) 2023-03-07
MX2023000165A (es) 2023-02-22
WO2022003421A3 (en) 2022-03-17
WO2022003421A2 (en) 2022-01-06
KR20230028502A (ko) 2023-02-28
AU2021298936A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
Xu et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis
Lue et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks
Prentice et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
Bailo et al. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development
Nuermberger et al. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections
Duncan et al. Prospects for new antitubercular drugs
Dorman et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial
Ammerman et al. Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis
De Jager et al. Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial
Temple et al. Rifapentine: its role in the treatment of tuberculosis
Rosenthal et al. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis
Tato et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates
Dutta et al. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice
Zheng et al. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models
Bradford et al. Multiple drug–resistant tuberculosis
WO2014080378A1 (en) Phenothiazine derivatives and their use against tuberculosis
WO2020144197A1 (en) Combination in the treatment of nontuberculous mycobacterial diseases
CN117045657A (zh) 一种药物组合及其应用
JP2023533472A (ja) 肺非結核性真菌感染症を治療するための三重抗生物質固定用量コンビネーション製品、投与レジメン、方法及びキット
TW202045180A (zh) 治療纖維化之方法
Routy et al. Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir
CN116406270A (zh) 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
CN119564683B (zh) 一种抗分枝杆菌感染的联合增效药物组合物
Kaur et al. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria
Miao et al. Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260210